SCHEMBL7019882

SCHEMBL7019882

N#Cc1c(N)nc(OCc2cccnc2)c(C#N)c1Cc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SQOR Q9Y6N5 2/20 0.45
MGMT P16455 1/20 0.44
KDM4E B2RXH2 3/20 0.43
GLA P06280 1/20 0.43
GAA P10253 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
RXFP1 Q9HBX9 1/20 0.41
MAPK10 P53779 2/20 0.41
ROCK2 O75116 1/20 0.41
CSF1R P07333 1/20 0.41
MAPK1 P28482 1/20 0.41
MAPK8 P45983 1/20 0.41
MAPK9 P45984 1/20 0.41
CSNK1D P48730 1/20 0.41
PRKD2 Q9BZL6 1/20 0.41
ADORA1 P30542 5/20 0.40
ADORA2A P29274 3/20 0.40
HTT P42858 2/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3545741 0.84 RXFP1 (0.55) SQORMGMTKDM4EGLAGAA
SCHEMBL7022670 0.81 RPS27 (0.52) SQORKDM4EMEN1KMT2AMAPK10
SCHEMBL7018457 0.78 ALDH1A1 (0.64) SQORMGMTKDM4EGLAGAA
SCHEMBL7015503 0.78 KDM4E (0.46) SQORKDM4EMEN1KMT2ARXFP1
SCHEMBL7017972 0.78 ALDH1A1 (0.49) SQORMGMTKDM4EGLAGAA
SCHEMBL7021742 0.77 ADORA1 (0.61) KDM4EGLAGAAMEN1KMT2A
SCHEMBL27975057 0.77 MEN1 (0.49) KDM4EMEN1KMT2ARXFP1MAPK1
SCHEMBL26010519 0.72 ADORA1 (0.52) SQORKDM4EGLAMEN1KMT2A
SCHEMBL6362719 0.72 MGMT (0.63) SQORMGMTADORA1ADORA2ALMNA
SCHEMBL6442519 0.72 MGMT (0.46) SQORMGMTKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030232860-A1 Medicine comprising dicyanopyridine derivative ASTELLAS PHARMA INC. (JP) 2003-12-18 US disclosed
EP-1302463-A1 MEDICINE COMPRISING DICYANOPYRIDINE DERIVATIVE YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2003-04-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232860-A1 Medicine comprising dicyanopyridine derivative KCNN3, KCNN2, KCNN1 SQOR 846/4885MGMT 2000/4885KDM4E 369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.